NY-Presbyterian Hospital announces participation in trial for hard-to-treat hypertension

October 25, 2012, New York- Presbyterian Hospital

Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.

Clinical trials of the Symplicity renal denervation system from Medtronic are underway at both NewYork-Presbyterian Hospital/Weill Cornell Medical Center and NewYork-Presbyterian Hospital/Columbia University Medical Center, which is the leading clinical-trial site in metropolitan New York. If successful, this investigational procedure—which deviates from traditional pharmaceutical therapies in favor of a minimally that aims to down-regulate overactive nerves in the body that can cause rising blood pressure—could turn the tide for the many Americans affected by treatment-resistant hypertension.

"Hypertension is a serious health problem, and those with drug-resistant hypertension are at the greatest risk of developing , including heart attack, stroke and death," says Dr. Ajay J. Kirtane, an interventional cardiologist and chief academic officer of the Center for Interventional at NewYork-Presbyterian/Columbia University Medical Center. Dr. Kirtane is leading the study at NewYork-Presbyterian/Columbia. "In earlier studies, the Symplicity renal denervation system reduced systolic blood pressure by an average of 33 millimeters, a remarkable amount for patients with such severe hypertension. If the results are duplicated in this pivotal clinical trial, we may have discovered an effective treatment that will help millions of Americans."

"The Symplicity renal denervation system may someday be an attractive alternative for patients in the U.S. who have uncontrolled hypertension despite treatment with many medications," says Dr. Samuel J. Mann, a leading hypertension specialist at NewYork-Presbyterian/Weill Cornell and professor of clinical medicine at Weill Cornell Medical College, who is leading the study at NewYork-Presbyterian/Weill Cornell.

Researchers think that hyperactivity of the sympathetic nervous system, which connects the brain, heart, blood vessels and kidneys—each of which plays an important role in blood pressure—contributes to resistant hypertension. The Simplicity renal denervation system seeks to reduce the drive of the sympathetic nervous system by preventing it from sending out erroneous signals to the brain to increase blood pressure.

In the Symplicity system, a catheter is introduced through a very small incision in the groin and is threaded up into the renal arteries that supply blood to the kidneys. Once in place, the catheter sends out radio waves at a preset frequency generated by a proprietary generator, which target the sympathetic nerves without damaging the surrounding blood vessels. The catheter is removed once the radiofrequency waves have been delivered at multiple locations along the artery.

Affecting about 76.4 million people over the age of 20 nationwide, hypertension is a common cardiovascular disorder in which blood-pressure levels are abnormally elevated—systolic blood pressure of 140 or greater or diastolic blood pressure of 90 or greater—over a sustained period of time. is considered to be treatment-resistant when a patient's blood pressure remains high despite treatment with three or more antihypertensive medications.

The U.S. Food and Drug Administration approved the Symplicity HTN-3 study protocol in July 2011. NewYork-Presbyterian Hospital is currently enrolling patients for the study, which altogether will randomize 530 patients to receive either renal denervation combined with antihypertensive medications or treatment with antihypertensive medications alone. To qualify, patients must meet certain criteria, including having systolic of at least 160 mmHg in the physicians's office despite treatment with adequate doses of at least three antihypertensive medications.

Explore further: Study tests new therapy for treatment-resistant hypertension

Related Stories

Study tests new therapy for treatment-resistant hypertension

June 28, 2012
(Medical Xpress) -- Treatment-resistant hypertension affects nearly 6 million Americans and another 94 million people worldwide and is associated with increased cardiovascular risk, including stroke and heart attack, as well ...

Renal denervation achieves significant and sustained blood pressure reduction

August 27, 2012
Renal denervation leads to significant and sustained blood pressure reduction for up to 18 months in patients with treatment resistant hypertension, according to research presented at ESC Congress 2012. The new clinical data ...

Renal denervation treats resistant hypertension in real world patient populations

August 27, 2012
Renal denervation successfully treats patients with resistant hypertension in real world patient populations, according to a study presented at ESC Congress 2012. The findings were presented by Dr Darren Mylotte from France.

Simple procedure lowers blood pressure in kidney disease patients

May 17, 2012
Disrupting certain nerves in the kidneys can safely and effectively lower blood pressure in patients with chronic kidney disease (CKD) and hypertension, according to a study appearing in an upcoming issue of the Journal of ...

Renal denervation improves blood pressure and arterial stiffness

August 27, 2012
Renal denervation improves blood pressure and arterial stiffness in patients with therapy resistant hypertension, according to research presented at ESC Congress 2012 by Mr Klaas Franzen from the University Hospital of Schleswig-Holstein. ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.